Cagrilintide
A long-acting amylin receptor agonist studied both alone and combined with semaglutide (as CagriSema) to act on a separate satiety pathway from GLP-1.
Research status: Phase 2/3 trial data; not yet independently approved.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Related in Weight Loss